For instance, Seung Hyuck Jeon and collaborators described a radiomic signature that predicts CD8+ tumor infiltration lymphocyte alterations and suggested its clinical utility to evaluate tumor immune status after chemoradiotherapy for rectal cancer patients [48]. The gene discussed is CD8A; the disease is neoplasm.